NICE technology appraisal guidance
Issued: April 2012
TA253
Boceprevir for the treatment of genotype 1 chronic hepatitis C
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta253
1 Guidance
1.1 Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:
-
who are previously untreated or
-
in whom previous treatment has failed.